Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31729297 | 0.85 | SSTR4 (0.45) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10132049 | 0.84 | MAPT (0.52) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7404210 | 0.78 | PKM (0.41) | MAPTSMN1; SMN2LMNADPP4PKM | |
| SCHEMBL6344652 | 0.78 | MAPT (0.54) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7010780 | 0.76 | MAPT (0.53) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12000330 | 0.76 | KDM4E (0.41) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL38652331 | 0.76 | PKM (0.44) | MAPTPKMNLRP3TP53HTT | |
| SCHEMBL1477877 | 0.76 | PKM (0.44) | MAPTPKMNLRP3TP53HTT | |
| SCHEMBL932150 | 0.75 | MAPT (0.58) | MAPTMAPK1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9370451 | 0.75 | MAPT (0.49) | MAPTMAPK1ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462050-B1 | FOR TREATING OR PREVENTING VENOUS, CARDIOGENIC, AND ARTERIAL THROMBOSIS/EMBOLISM, ATHERSCLEROSIS, AND FOR LOWERING PROPENSITY OF DEVICES THAT COME INTO CONTACT WITH BLOOD TO CLOT BLOOD | MERCK & CO., INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020035115-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002009711-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035115-A1 | Thrombin inhibitors | TFPI, PLAT, F2 | MAPT 4183/4885MAPK1 3037/4885SMN1; SMN2 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.